お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は遺伝子組換えワクチン市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは遺伝子組換えワクチンの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の遺伝子組換えワクチン市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは遺伝子組換えワクチンのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に遺伝子組換えワクチン市場を分類しています。本研究に含まれる主な企業は：Merck & Co., Inc、Green Cross Corporation、Pfizer Inc.、Bayer AG、Sanofi S A.、Protein Science Corporation、GlaxoSmithKline Plc.、Novartis AG、Bharat Biotech、AstraZeneca Plc.、Johnson & Johnson、Emergent BioSolutions Inc、Novavax, Inc、Serum Institute of India Pvt. Ltd、Dynavax Technologies Corporation

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Subunit Recombinant Vaccines
    Attenuated Recombinant Vaccines
    Vector Recombinant Vaccines

用途別の市場セグメント：
    Recombinant Human Vaccines
    Animal Recombinant Vaccines

本レポートの詳細内容
世界の遺伝子組換えワクチン市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、遺伝子組換えワクチンタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の遺伝子組換えワクチン収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の遺伝子組換えワクチン市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、遺伝子組換えワクチン市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

遺伝子組換えワクチンのレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：遺伝子組換えワクチンのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：遺伝子組換えワクチンの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章遺伝子組換えワクチン企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：遺伝子組換えワクチンの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：遺伝子組換えワクチンの主要企業の概要を提供し、製品の説明と仕様、遺伝子組換えワクチンの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease. 
These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.

 Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.

Market Analysis and Insights: Global Recombinant Vaccines Market
The global Recombinant Vaccines market is projected to grow from US$ 9175 million in 2024 to US$ 17170 million by 2030, at a Compound Annual Growth Rate (CAGR) of 11.0% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Recombinant Vaccines market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Recombinant Vaccines, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Recombinant Vaccines, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Vaccines revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Recombinant Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Recombinant Vaccines revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG and Bharat Biotech, etc.
Market Segmentation
By Company
    Merck & Co., Inc
    Green Cross Corporation
    Pfizer Inc.
    Bayer AG
    Sanofi S A.
    Protein Science Corporation
    GlaxoSmithKline Plc.
    Novartis AG
    Bharat Biotech
    AstraZeneca Plc.
    Johnson & Johnson
    Emergent BioSolutions Inc
    Novavax, Inc
    Serum Institute of India Pvt. Ltd
    Dynavax Technologies Corporation

Segment by Type
    Subunit Recombinant Vaccines
    Attenuated Recombinant Vaccines
    Vector Recombinant Vaccines

Segment by Application
    Recombinant Human Vaccines
    Animal Recombinant Vaccines

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Recombinant Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Vaccines companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Vaccines revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Recombinant Vaccines Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Subunit Recombinant Vaccines
    Table 3. Key Players of Attenuated Recombinant Vaccines
    Table 4. Key Players of Vector Recombinant Vaccines
    Table 5. Global Recombinant Vaccines Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Recombinant Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Recombinant Vaccines Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Recombinant Vaccines Market Share by Region (2019-2024)
    Table 9. Global Recombinant Vaccines Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Recombinant Vaccines Market Share by Region (2025-2030)
    Table 11. Recombinant Vaccines Market Trends
    Table 12. Recombinant Vaccines Market Drivers
    Table 13. Recombinant Vaccines Market Challenges
    Table 14. Recombinant Vaccines Market Restraints
    Table 15. Global Recombinant Vaccines Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Recombinant Vaccines Revenue Share by Players (2019-2024)
    Table 17. Global Top Recombinant Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2023)
    Table 18. Global Recombinant Vaccines Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Recombinant Vaccines Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Recombinant Vaccines, Headquarters and Area Served
    Table 21. Global Key Players of Recombinant Vaccines, Product and Application
    Table 22. Global Key Players of Recombinant Vaccines, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Recombinant Vaccines Revenue Market Share by Type (2019-2024)
    Table 26. Global Recombinant Vaccines Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Recombinant Vaccines Revenue Market Share by Type (2025-2030)
    Table 28. Global Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Recombinant Vaccines Revenue Share by Application (2019-2024)
    Table 30. Global Recombinant Vaccines Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Recombinant Vaccines Revenue Share by Application (2025-2030)
    Table 32. North America Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Recombinant Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Recombinant Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Recombinant Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Recombinant Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Recombinant Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Recombinant Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Recombinant Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Recombinant Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Recombinant Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Recombinant Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Recombinant Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Recombinant Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Recombinant Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Recombinant Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Recombinant Vaccines Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Recombinant Vaccines Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Recombinant Vaccines Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Recombinant Vaccines Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Recombinant Vaccines Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Merck & Co., Inc Company Details
    Table 65. Merck & Co., Inc Business Overview
    Table 66. Merck & Co., Inc Recombinant Vaccines Product
    Table 67. Merck & Co., Inc Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 68. Merck & Co., Inc Recent Developments
    Table 69. Green Cross Corporation Company Details
    Table 70. Green Cross Corporation Business Overview
    Table 71. Green Cross Corporation Recombinant Vaccines Product
    Table 72. Green Cross Corporation Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 73. Green Cross Corporation Recent Developments
    Table 74. Pfizer Inc. Company Details
    Table 75. Pfizer Inc. Business Overview
    Table 76. Pfizer Inc. Recombinant Vaccines Product
    Table 77. Pfizer Inc. Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 78. Pfizer Inc. Recent Developments
    Table 79. Bayer AG Company Details
    Table 80. Bayer AG Business Overview
    Table 81. Bayer AG Recombinant Vaccines Product
    Table 82. Bayer AG Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 83. Bayer AG Recent Developments
    Table 84. Sanofi S A. Company Details
    Table 85. Sanofi S A. Business Overview
    Table 86. Sanofi S A. Recombinant Vaccines Product
    Table 87. Sanofi S A. Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 88. Sanofi S A. Recent Developments
    Table 89. Protein Science Corporation Company Details
    Table 90. Protein Science Corporation Business Overview
    Table 91. Protein Science Corporation Recombinant Vaccines Product
    Table 92. Protein Science Corporation Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 93. Protein Science Corporation Recent Developments
    Table 94. GlaxoSmithKline Plc. Company Details
    Table 95. GlaxoSmithKline Plc. Business Overview
    Table 96. GlaxoSmithKline Plc. Recombinant Vaccines Product
    Table 97. GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 98. GlaxoSmithKline Plc. Recent Developments
    Table 99. Novartis AG Company Details
    Table 100. Novartis AG Business Overview
    Table 101. Novartis AG Recombinant Vaccines Product
    Table 102. Novartis AG Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 103. Novartis AG Recent Developments
    Table 104. Bharat Biotech Company Details
    Table 105. Bharat Biotech Business Overview
    Table 106. Bharat Biotech Recombinant Vaccines Product
    Table 107. Bharat Biotech Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 108. Bharat Biotech Recent Developments
    Table 109. AstraZeneca Plc. Company Details
    Table 110. AstraZeneca Plc. Business Overview
    Table 111. AstraZeneca Plc. Recombinant Vaccines Product
    Table 112. AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 113. AstraZeneca Plc. Recent Developments
    Table 114. Johnson & Johnson Company Details
    Table 115. Johnson & Johnson Business Overview
    Table 116. Johnson & Johnson Recombinant Vaccines Product
    Table 117. Johnson & Johnson Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 118. Johnson & Johnson Recent Developments
    Table 119. Emergent BioSolutions Inc Company Details
    Table 120. Emergent BioSolutions Inc Business Overview
    Table 121. Emergent BioSolutions Inc Recombinant Vaccines Product
    Table 122. Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 123. Emergent BioSolutions Inc Recent Developments
    Table 124. Novavax, Inc Company Details
    Table 125. Novavax, Inc Business Overview
    Table 126. Novavax, Inc Recombinant Vaccines Product
    Table 127. Novavax, Inc Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 128. Novavax, Inc Recent Developments
    Table 129. Serum Institute of India Pvt. Ltd Company Details
    Table 130. Serum Institute of India Pvt. Ltd Business Overview
    Table 131. Serum Institute of India Pvt. Ltd Recombinant Vaccines Product
    Table 132. Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 133. Serum Institute of India Pvt. Ltd Recent Developments
    Table 134. Dynavax Technologies Corporation Company Details
    Table 135. Dynavax Technologies Corporation Business Overview
    Table 136. Dynavax Technologies Corporation Recombinant Vaccines Product
    Table 137. Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2019-2024) & (US$ Million)
    Table 138. Dynavax Technologies Corporation Recent Developments
    Table 139. Research Programs/Design for This Report
    Table 140. Key Data Information from Secondary Sources
    Table 141. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Recombinant Vaccines Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Recombinant Vaccines Market Share by Type: 2023 VS 2030
    Figure 3. Subunit Recombinant Vaccines Features
    Figure 4. Attenuated Recombinant Vaccines Features
    Figure 5. Vector Recombinant Vaccines Features
    Figure 6. Global Recombinant Vaccines Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Recombinant Vaccines Market Share by Application: 2023 VS 2030
    Figure 8. Recombinant Human Vaccines Case Studies
    Figure 9. Animal Recombinant Vaccines Case Studies
    Figure 10. Recombinant Vaccines Report Years Considered
    Figure 11. Global Recombinant Vaccines Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Recombinant Vaccines Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Recombinant Vaccines Market Share by Region: 2023 VS 2030
    Figure 14. Global Recombinant Vaccines Market Share by Players in 2023
    Figure 15. Global Top Recombinant Vaccines Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Recombinant Vaccines Revenue in 2023
    Figure 17. North America Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Recombinant Vaccines Market Share by Type (2019-2030)
    Figure 19. North America Recombinant Vaccines Market Share by Application (2019-2030)
    Figure 20. North America Recombinant Vaccines Market Share by Country (2019-2030)
    Figure 21. United States Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Recombinant Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 24. Europe Recombinant Vaccines Market Share by Type (2019-2030)
    Figure 25. Europe Recombinant Vaccines Market Share by Application (2019-2030)
    Figure 26. Europe Recombinant Vaccines Market Share by Country (2019-2030)
    Figure 27. Germany Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. China Recombinant Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 34. China Recombinant Vaccines Market Share by Type (2019-2030)
    Figure 35. China Recombinant Vaccines Market Share by Application (2019-2030)
    Figure 36. Asia Recombinant Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. Asia Recombinant Vaccines Market Share by Type (2019-2030)
    Figure 38. Asia Recombinant Vaccines Market Share by Application (2019-2030)
    Figure 39. Asia Recombinant Vaccines Market Share by Region (2019-2030)
    Figure 40. Japan Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. South Korea Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America Recombinant Vaccines Market Size YoY (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Recombinant Vaccines Market Share by Type (2019-2030)
    Figure 48. Middle East, Africa, and Latin America Recombinant Vaccines Market Share by Application (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Recombinant Vaccines Market Share by Country (2019-2030)
    Figure 50. Brazil Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Mexico Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Turkey Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Israel Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. GCC Countries Recombinant Vaccines Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Merck & Co., Inc Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 57. Green Cross Corporation Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 58. Pfizer Inc. Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 59. Bayer AG Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 60. Sanofi S A. Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 61. Protein Science Corporation Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 62. GlaxoSmithKline Plc. Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 63. Novartis AG Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 64. Bharat Biotech Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 65. AstraZeneca Plc. Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 66. Johnson & Johnson Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 67. Emergent BioSolutions Inc Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 68. Novavax, Inc Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 69. Serum Institute of India Pvt. Ltd Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 70. Dynavax Technologies Corporation Revenue Growth Rate in Recombinant Vaccines Business (2019-2024)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed